Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg
Kelly A, Arslanian S, Hesse D, Iversen A, Körner A, Schmidt S, Sørrig R, Weghuber D, Jastreboff A. Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg. Obesity 2023, 31: 2139-2149. PMID: 37196421, DOI: 10.1002/oby.23808.Peer-Reviewed Original ResearchConceptsWeekly subcutaneous semaglutideBMI categoriesSubcutaneous semaglutideWeek 68Glucagon-like peptide-1 receptor agonistsObesity thresholdPeptide-1 receptor agonistsHigh-intensity physical activityObesity class IIIOverweight BMI categoryLogistic regression modelsOverweight BMIReceiving placeboTeens trialLifestyle interventionReceptor agonistPhysical activityPlaceboBMISemaglutideParticipants' BMIClass IIIOverall populationPhase 3aHealthy nutritionRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J, Frias J, Jastreboff A, Du Y, Lou J, Gurbuz S, Thomas M, Hartman M, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet 2023, 402: 529-544. PMID: 37385280, DOI: 10.1016/s0140-6736(23)01053-x.Peer-Reviewed Original ResearchConceptsGlucose-dependent insulinotropic polypeptideType 2 diabetesGLP-1 receptor agonistsEscalation groupPhase 2 trialReceptor agonistDulaglutide groupPlacebo groupStudy treatmentGLP-1Interactive web response systemModerate gastrointestinal adverse eventsType 2 diabetes managementCurrent consensus guidelinesGastrointestinal adverse eventsWeb response systemPhase 1 studyStudy site personnelHealth care centersGlucagon receptor agonistPhase 3 programRange of dosesPhase 2 dataBaseline HbAGlycaemic targetsNew Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Jastreboff A, Kushner R. New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. Annual Review Of Medicine 2023, 74: 125-139. PMID: 36706749, DOI: 10.1146/annurev-med-043021-014919.Peer-Reviewed Original ResearchConceptsGLP-1 RAsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsAnti-obesity therapeuticsTreatment of obesityMechanism-based treatmentsNeurobiology of obesityObesity treatmentReceptor agonistGLP-1Obesity therapeuticsEffective treatmentObesityHalf of AmericansFirst agentTreatmentTherapeuticsAgonistsAgents